Palomar Medical Presents New Acne Product at the American Academy of Dermatology Annual Meeting
February 04 2011 - 10:51AM
Palomar Medical Technologies, Inc. (Nasdaq:PMTI), a leading
researcher and developer of light-based systems for cosmetic
treatments, announced today the launch of the Acleara™ acne
clearing system at the 69th Annual Meeting of the American Academy
of Dermatology (AAD) in New Orleans, Louisiana, from February 5th
through February 7th.
The Acleara acne clearing system uses broad band light and
suction to treat mild to moderate acne including acne vulgaris,
comedonal and pustular acne. With the Acleara system, practitioners
can treat a full face in less than 15 minutes with no numbing or
cooling gels and no anesthetic costs.
Acleara provides deep cleaning of pores by extracting
accumulated sebaceous material, and provides targeted heating of
sebaceous glands. The light activates endogenous porphyrins to
destroy P. acnes and reduces sebum production through photodynamic
action.
According to Dr. Robert Berger, a practicing Dermatologist from
Waldorf, MD and an Associate Professor of Dermatology from Johns
Hopkins School of Medicine, regarding the Acleara system, "I have
performed over 15,000 treatments over 5 years using a number of
different technologies to treat acne. The Acleara system has proven
more effective, less painful and it delivers superior results as
compared to any previous technologies I have tried in treating
active acne."
Joseph P. Caruso, Chief Executive Officer, commented, "We are
very excited about this product launch. It is a fantastic addition
to our robust family of products and allows us to address the
enormous acne market. The American Academy of Dermatology reports
that Acne vulgaris is the most common skin condition in the United
States. Up to 50 million Americans have acne and 85 percent of all
U.S. teenagers have acne. The Acleara system offers physicians
advanced technology to both deep clean and treat the skin."
Mr. Caruso continued, "Many who suffer from acne cannot tolerate
or do not want to have their acne treated by drugs. The Acleara
system is an excellent alternative for consumers and physicians
alike."
Attendees at the AAD Annual Meeting in New Orleans can learn
about the Acleara acne clearing system at Palomar's exhibition hall
booth, #811.
About Palomar Medical Technologies Inc: Palomar
designs, produces and sells the most advanced cosmetic lasers and
intense pulsed light (IPL) systems to dramatically improve the
appearance of women's and men's skin. For over 15 years, Palomar
has pioneered the science of using lasers and light to improve
appearances. As the industry's technology leader, Palomar has
invested in creating cosmetic laser and IPL systems that put real
value in the hands of physicians and other professionals to benefit
consumers. Thousands of physicians worldwide trust and depend on
Palomar technology to not only introduce new aesthetic treatments
such as advanced laser hair removal, laser liposuction, skin
resurfacing, acne, laser treatments for scars, wrinkle treatment,
stretch marks (striae), and photofacials for pigmented and vascular
lesions, but to also make them robust, faster, more powerful, and
more comfortable for those being treated. In June 2009, Palomar
became the first company to receive a 510(k) over-the-counter
("OTC") clearance from the FDA for a new, patented, home-use, laser
device for the treatment of fine lines and wrinkles around the eyes
(periorbital wrinkles). This OTC clearance allows Palomar to market
and sell the PaloVia™ Skin Renewing Laser™ directly to consumers
without a prescription.
For more information on Palomar and its products, visit
Palomar's website at palomarmedical.com or palovia.com. To continue
receiving the most up-to-date information and latest news on
Palomar as it happens, sign up to receive automatic e-mail alerts
by going to the Investor Relations' section of
palomarmedical.com.
With the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements, including, but not limited to, statements relating to
new markets, future royalty amounts due from third parties,
development and introduction of new products, and financial and
operating projections. These forward-looking statements are neither
promises nor guarantees, but involve risk and uncertainties that
may individually or mutually impact the matters herein, and cause
actual results, events and performance to differ materially from
such forward-looking statements. These risk factors include, but
are not limited to, results of future operations, technological
difficulties in developing or introducing new products, the results
of future research, lack of product demand and market acceptance
for current and future products, the effect of economic conditions,
challenges in managing joint ventures and research with third
parties and government contracts, the impact of competitive
products and pricing, governmental regulations with respect to
medical devices, including whether FDA clearance will be obtained
for future products and additional applications, the results of
litigation, difficulties in collecting royalties, potential
infringement of third-party intellectual property rights, factors
affecting the Company's future income and resulting ability to
utilize its NOLs, and/or other factors, which are detailed from
time to time in the Company's SEC reports, including the report on
Form 10-K for the year ended December 31, 2009 and the Company's
quarterly reports on Form 10-Q. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof. The Company undertakes no obligation to
release publicly the result of any revisions to these
forward-looking statements that may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events.
CONTACT: Kerry McAnistan
Investor Relations Assistant
Palomar Medical Technologies, Inc.
781-993-2411
ir@palomarmedical.com
Palomar Medical Technologies, Inc. (MM) (NASDAQ:PMTI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Palomar Medical Technologies, Inc. (MM) (NASDAQ:PMTI)
Historical Stock Chart
From Jul 2023 to Jul 2024